PTEN loss associates with type I and II IFN response in prostate cancer

被引：0
作者：
Vidotto, Thiago [1 ]
Squire, Jeremy Andrew [2 ]
Koti, Madhuri [2 ]
机构：
[1] Univ Sao Paulo, Ribeirao Preto, SP, Brazil
[2] Queens Univ, Kingston, ON, Canada
来源：
CLINICAL CANCER RESEARCH | 2018年 / 24卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B30
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [41] Loss of expression of bone morphogenetic proteins receptor type II in prostate cancer patients
    Kim, IY
    Ahn, H
    Lee, DH
    Morton, RA
    Kim, SJ
    JOURNAL OF UROLOGY, 2004, 171 (04) : 157 - 157
  • [42] PTEN, a putative prostate tumor suppressor gene: Loss of heterozygosity in localized prostate cancer.
    Rubin, MA
    Reid, KA
    Wang, SL
    Lequesne, E
    Olsson, CA
    Parsons, R
    MODERN PATHOLOGY, 1998, 11 (01) : 94A - 94A
  • [43] Angiotensin II type I receptor antagonist as an angiogenic inhibitor in prostate cancer
    Kosaka, Takeo
    Miyajima, Akira
    Takayama, Eiji
    Kikuchi, Eiji
    Nakashima, Jun
    Higashi, Takashi
    Asano, Tomohiko
    Sakamoto, Michiie
    Okita, Hajime
    Murai, Masaru
    Hayakawa, Masamichi
    PROSTATE, 2007, 67 (01) : 41 - 49
  • [44] Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
    Damien J. Zanker
    Katie L. Owen
    Nikola Baschuk
    Alex J. Spurling
    Belinda S. Parker
    Cancer Immunology, Immunotherapy, 2021, 70 : 2125 - 2138
  • [45] Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
    Zanker, Damien J.
    Owen, Katie L.
    Baschuk, Nikola
    Spurling, Alex J.
    Parker, Belinda S.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2125 - 2138
  • [46] Commentary: On watching the watchers: IDO and type I/II IFN
    Puccetti, Paolo
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (04) : 876 - 879
  • [47] Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
    Leinonen, Katri A.
    Saramaki, Outi R.
    Furusato, Bungo
    Kimura, Takahiro
    Takahashi, Hiroyuki
    Egawa, Shin
    Suzuki, Hiroyoshi
    Keiger, Kerri
    Hahm, Sung Ho
    Isaacs, William B.
    Tolonen, Teemu T.
    Stenman, Ulf-Hakan
    Tammela, Teuvo L. J.
    Nykter, Matti
    Bova, G. Steven
    Visakorpi, Tapio
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (12) : 2333 - 2344
  • [48] PTEN LOSS IN LOCALIZED PROSTATE CANCER: CLINICOPATHOLOGIC PARAMETERS AND RELATIONSHIP WITH DISEASE OUTCOME
    Chery, Lisly
    Wright, Johnathan L.
    Lin, Daniel W.
    Qu, Xiaoyu
    Fang, Min
    Stanford, Janet
    JOURNAL OF UROLOGY, 2014, 191 (04) : E932 - E933
  • [49] Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)
    Jamaspishvili, Tamara
    Patel, Palak G.
    Niu, Yi
    Vidotto, Thiago
    Caven, Isabelle
    Livergant, Rachel
    Fu, Winnie
    Kawashima, Atsunari
    How, Nathan
    Okello, John B.
    Guedes, Liana B.
    Ouellet, Veronique
    Picanco, Clarissa
    Koti, Madhuri
    Reis, Rodolfo B.
    Saad, Fred
    Mes-Masson, Anne-Marie
    Lotan, Tamara L.
    Squire, Jeremy A.
    Peng, Yingwei P.
    Siemens, D. Robert
    Berman, David M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (11): : 1098 - 1104
  • [50] Understanding the role of hypoxia and PTEN loss in driving prostate cancer progression.
    Suvac, Alexandru
    Rebello, Richard
    Lyons, Stephen
    Bristow, Robert G.
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
12345